Carl Byrnes

Stock Analyst at Northland Securities

(0.26)
# 4,200
Out of 4,376 analysts
306
Total ratings
36.9%
Success rate
-4.1%
Average return

Stocks Rated by Carl Byrnes

Connect Biopharma Holdings
Apr 24, 2026
Maintained: Buy
Price Target: $7.5
Current: $2.17
Upside: +245.62%
MiMedx Group
Apr 17, 2026
Maintained: Buy
Price Target: $10$6
Current: $3.74
Upside: +60.43%
ARS Pharmaceuticals
Apr 15, 2026
Maintained: Buy
Price Target: $25
Current: $8.56
Upside: +192.06%
AVITA Medical
Mar 26, 2026
Maintained: Buy
Price Target: $10
Current: $4.18
Upside: +139.23%
BioLife Solutions
Mar 24, 2026
Reiterated: Buy
Price Target: $34
Current: $26.65
Upside: +27.58%
TriSalus Life Sciences
Mar 23, 2026
Rated: Buy
Price Target: $13$8
Current: $3.17
Upside: +152.37%
Spectral AI
Mar 19, 2026
Maintained: Buy
Price Target: $6
Current: $1.89
Upside: +217.46%
SANUWAVE Health
Mar 16, 2026
Maintained: Buy
Price Target: $55
Current: $14.76
Upside: +272.63%
BrainsWay
Jan 22, 2026
Maintained: Buy
Price Target: $12$15
Current: $13.89
Upside: +7.99%
Alvotech
Nov 14, 2025
Maintained: Buy
Price Target: $10
Current: $3.54
Upside: +182.49%
Reiterated: Buy
Price Target: $9$4
Current: $0.4274
Upside: +835.89%
Maintained: Buy
Price Target: $5
Current: $0.6585
Upside: +659.30%
Maintained: Hold
Price Target: $3
Current: $3.13
Upside: n/a
Rated: Hold
Price Target: $2$1.25
Current: $13.93
Upside: n/a
Initiated Coverage: Buy
Price Target: $8
Current: $1.96
Upside: n/a
Downgraded: Sell
Price Target: $8$1
Current: $0.0001
Upside: n/a
Maintained: Buy
Price Target: $10$2
Current: $0.0002
Upside: n/a
Maintained: Buy
Price Target: $4$2
Current: $32.14
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $2.25
Upside: n/a
Initiated Coverage: Buy
Price Target: $45
Current: $57.27
Upside: n/a
Initiated Coverage: Buy
Price Target: n/a
Current: $14.44
Upside: n/a